Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Shoji, Hirokazu; Furukawa, Naoto; Yoshizawa, Yoriko; Tsunemi, Taihei; Nagai, Akiko; Kawaguchi, Ryuji; Tanase, Yasuhito; Yoshida, Shozo; Kobayashi, Hiroshi

doi:10.3892/or.2011.1456

Cited by 23 publications

(17 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the basis of histological diagnosis after surgery, 38 cases were classified as EOCs; 18.4% (7/38) were diagnosed as CCC, 44.7% (17/38) as serous-type, and 10.5% (4/38) were with endometrioid- and mucinous-type EOCs for both (Table 2). The distribution of EOC subtypes was similar to the typical incidence rate of these subtypes among Japanese women [2]. …”

Section: Resultssupporting

confidence: 57%

See 1 more Smart Citation

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundThere is currently no reliable serum biomarker for ovarian clear cell carcinoma (CCC), a highly lethal histological subtype of epithelial ovarian cancer (EOC). Previously, using a proteome-based approach, we identified tissue factor pathway inhibitor 2 (TFPI2) as a candidate serum biomarker for CCC. In this study, we sought to evaluate the clinical diagnostic performance of TFPI2 in preoperative prediction of CCC.MethodsSerum TFPI2 levels were measured in serum samples from a retrospective training set consisting of patients with benign and borderline ovarian tumors, EOC subtypes, and uterine diseases. Via receiver operating characteristic (ROC) analyses, we compared the diagnostic performance of TFPI2 with that of CA125 in discrimination of patients with ovarian CCC from other patient groups. The observed diagnostic performances were examined in a prospective validation set.ResultsThe 268-patient training set included 29 patients with ovarian CCC. Unlike CA125, which was also elevated in patients with endometriosis and several EOC subtypes, serum TFPI2 levels were specifically elevated only in ovarian CCC patients, consistent with the mRNA expression pattern in tumor tissues. The area under the ROC curve (AUC) of serum TFPI2 was obviously higher than that of CA125 for discrimination of CCC from other ovarian diseases (AUC = 0.891 versus 0.595). Applying a cut-off value of 280 pg/mL, TFPI2 could distinguish early-stage (FIGO I and II) CCC from endometriosis with 72.2% sensitivity, 93.3% specificity, and 88.8% accuracy. Similar results were confirmed in an independent 156-patient prospective validation set.ConclusionsTFPI2 is a useful serum biomarker for preoperative clinical diagnosis of CCC.

show abstract

Section: Resultssupporting

confidence: 57%

“…CCC is a rare subtype with an incidence of <5% of all EOC in Western countries. By contrast, in Japan, the incidence of CCC has been increasing, representing >20% of cases [2]. The clinical and biological characteristics of CCC differ from those of other EOC subtypes.…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer (OC) is the most lethal malignant gynecological cancer with the majority of patients diagnosed at the advanced stage. [1][2][3] Despite the remarkable progress in the treatment of OC including surgical resection, chemotherapy and radiotherapy, the 5-year overall survival rate of the OC patients remains less than 40%. 4 OC has a high recurrence rate and tends to develop the resistance to the current therapy strategies.…”

Section: Introductionmentioning

confidence: 99%

<p>MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9</p>

Shi¹,

Yang²,

Zhang³

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Increasing evidence has revealed that the aberrant expression of microRNAs (miRNAs) plays vital roles in the development and progression of ovarian cancer. MiR-200a-3p was found to act as an oncogene in a variety of cancers, however, the expression and function of miR-200a-3p in ovarian cancer has not been characterized. Materials and methods: The expression of miR-200a-3p in ovarian cancer tissues and cell lines was detected by the RT-qPCR. The influence of miR-200a-3p on the growth of ovarian cancer cells was determined with the Cell Counting Kit-8 assay, colony formation and cell invasion assay. The binding of miR-200a-3p with the 3ʹ-untranslated region (UTR) of PDCH9 was detected by luciferase reporter assay. The expression of PCDH9 was investigated by RT-qPCR and Western blot analysis. Results: miR-200a-3p was up-regulated in ovarian cancer tissues and cell lines. Highly expressed miR-200a-3p was significantly associated with the tumor size, tumor metastasis and TNM stage. Overexpression of miR-200a-3p markedly promoted the proliferation, colony formation and invasion of ovarian cancer cells. Functional study uncovered that miR-200a-3p bound the 3ʹ-untranslated region (UTR) of PCDH9 and decreased the expression of PCDH9 in ovarian cancer cells. The expression of miR-200a-3p in ovarian cancer tissues was significantly negatively correlated with that of PCDH9. Restored PCDH9 inhibited the promoting effect of miR-200a-3p on the proliferation of ovarian cancer cells. Conclusion: Our results suggested the potential oncogenic function of miR-200a-3p via modulating PCDH9 in ovarian cancer.

show abstract

“…Epithelial ovarian cancer (EOC) accounts for 90% to 95% of all cases of ovarian cancer [2, 3]. However, the etiology of EOC is not well understood but is likely to involve both genetic and environmental factors [4]. Therefore, discovery of new genes related to EOC risk and survival, as well as understanding their mechanism may provide important clues for, early detection, precise diagnosis and personalized therapy for EOC patients.…”

Section: Introductionmentioning

confidence: 99%

Genetic variants of lncRNA HOTAIR and risk of epithelial ovarian cancer among Chinese women

Shang

Shi

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Ovarian cancer is one of the common female malignant tumors globally. However, exactly mechanism of ovarian cancer remained unknown. HOTAIR, a lncRNA in the mammalian HOXC locus, has been fully explored for its genetic variants, expression level and carcinogenesis, development and progression of multiple cancers, except for ovarian cancer. In this study, we hypothesized that abnormal expression of HOTAIR and common variants of HOTAIR are associated with risk of Epithelial ovarian cancer (EOC). We first evaluated the HOTAIR levels in 100 paired tissues of EOC patients and corresponding normal tissues. Results showed that the expression level of HOTAIR in EOC tissues was significantly higher than that in corresponding normal tissues. Then the genotyping analyses of HOTAIR gene was conducted in a Chinese population. The results indicated that rs4759314 and rs7958904 were significantly associated with EOC susceptibility. For rs4759314, the difference between the G allele (as the reference) and the A allele was statistically significant (adjusted OR, 1.34; 95% CI: 1.08–1.65; P = 6.8 × 10−3). For rs7958904, C allele was associated a significantly decreased EOC risk when compared with G allele (OR: 0.77; 95% CI: 0.67–0.89; P = 4.2 × 10−4). The study identified that HOTAIR variants could be a useful biomarker for the predisposition to EOC and for the early diagnosis of the disease.

show abstract

Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Abstract: Abstract. This review summarizes data from recent molecular genetic and epidemiology studies of the generic term 'female pelvic cancer'. The English-language literature was reviewed for genetic, epigenetic, epidemiologic and

Cited by 23 publications

References 58 publications

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

<p>MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9</p>

Genetic variants of lncRNA HOTAIR and risk of epithelial ovarian cancer among Chinese women

Contact Info

Product

Resources

About